- Home
- CBAT vs IMAB Comparison
CBAT vs IMAB Comparison
Compare CBAT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- IMAB
- Stock Information
- Founded
- CBAT 1999
- IMAB 2014
- Country
- CBAT China
- IMAB United States
- Employees
- CBAT N/A
- IMAB N/A
- Industry
- CBAT Industrial Machinery/Components
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CBAT Miscellaneous
- IMAB Health Care
- Exchange
- CBAT Nasdaq
- IMAB Nasdaq
- Market Cap
- CBAT 83.0M
- IMAB 79.9M
- IPO Year
- CBAT N/A
- IMAB 2020
- Fundamental
- Price
- CBAT $0.86
- IMAB $0.97
- Analyst Decision
- CBAT
- IMAB Strong Buy
- Analyst Count
- CBAT 0
- IMAB 3
- Target Price
- CBAT N/A
- IMAB $8.00
- AVG Volume (30 Days)
- CBAT 197.4K
- IMAB 263.0K
- Earning Date
- CBAT 03-14-2025
- IMAB 03-13-2025
- Dividend Yield
- CBAT N/A
- IMAB N/A
- EPS Growth
- CBAT N/A
- IMAB N/A
- EPS
- CBAT 0.12
- IMAB N/A
- Revenue
- CBAT $207,423,403.00
- IMAB $569,464.00
- Revenue This Year
- CBAT $0.46
- IMAB N/A
- Revenue Next Year
- CBAT $13.78
- IMAB N/A
- P/E Ratio
- CBAT $7.12
- IMAB N/A
- Revenue Growth
- CBAT 2.32
- IMAB N/A
- 52 Week Low
- CBAT $0.77
- IMAB $0.84
- 52 Week High
- CBAT $2.08
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- CBAT 41.36
- IMAB 46.51
- Support Level
- CBAT $0.85
- IMAB $0.96
- Resistance Level
- CBAT $0.92
- IMAB $1.04
- Average True Range (ATR)
- CBAT 0.04
- IMAB 0.05
- MACD
- CBAT -0.00
- IMAB -0.00
- Stochastic Oscillator
- CBAT 10.00
- IMAB 36.36
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).